(Q41592572)

English

Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).

scientific article published on December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 October 2017

Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). (English)

1 reference

Europe PubMed Central

4 October 2017

multicenter clinical trial

0 references

Helicobacter pylori

0 references

author name string

Takashi Kawai

1

1 reference

Europe PubMed Central

4 October 2017

Shin'ichi Takahashi

2

1 reference

Europe PubMed Central

4 October 2017

Hidekazu Suzuki

3

1 reference

Europe PubMed Central

4 October 2017

Hitoshi Sasaki

4

1 reference

Europe PubMed Central

4 October 2017

Akihito Nagahara

5

1 reference

Europe PubMed Central

4 October 2017

Daisuke Asaoka

6

1 reference

Europe PubMed Central

4 October 2017

Takeshi Matsuhisa

7

1 reference

Europe PubMed Central

4 October 2017

Tatsuhiro Masaoaka

8

1 reference

Europe PubMed Central

4 October 2017

Toshihiro Nishizawa

9

1 reference

Europe PubMed Central

4 October 2017

Masayuki Suzuki

10

1 reference

Europe PubMed Central

4 October 2017

Masayoshi Ito

11

1 reference

Europe PubMed Central

4 October 2017

Naoto Kurihara

12

1 reference

Europe PubMed Central

4 October 2017

Fumio Omata

13

1 reference

Europe PubMed Central

4 October 2017

Shigeaki Mizuno

14

1 reference

Europe PubMed Central

4 October 2017

Akira Torii

15

1 reference

Europe PubMed Central

4 October 2017

Kohei Kawakami

16

1 reference

Europe PubMed Central

4 October 2017

Toshifumi Ohkusa

17

1 reference

Europe PubMed Central

4 October 2017

Kengo Tokunaga

18

1 reference

Europe PubMed Central

4 October 2017

Tetsuya Mine

19

1 reference

Europe PubMed Central

4 October 2017

Nobuhiro Sakaki

20

1 reference

Europe PubMed Central

4 October 2017

publication date

1 December 2014

1 reference

Europe PubMed Central

4 October 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

4 October 2017

29 Suppl 4

1 reference

Europe PubMed Central

4 October 2017

29-32

1 reference

Europe PubMed Central

4 October 2017

Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Can Eradication Therapy for Helicobacter pylori Really Improve the Thrombocytopenia in Idiopathic Thrombocytopenic Purpura? Our Experience and a Literature Review

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

A new approach for elimination of gastric cancer deaths in Japan

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Edkins and a century of acid suppression

1 reference

https://api.crossref.org/works/10.1111%2FJGH.12796

21 January 2018

Identifiers

10.1111/JGH.12796

1 reference

Europe PubMed Central

4 October 2017

1 reference

Europe PubMed Central

4 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41592572&oldid=1532765625"